A Phase III trial presented at ASCO 2026 and simultaneously published in The Lancet shows that pairing a precision TROP2-targeting weapon with the world’s most prescribed immunotherapy rewrites what is…
A Phase 3 trial just cut the risk of death by 60 percent in metastatic pancreatic cancer, a disease that has resisted nearly every therapeutic advance for four decades. The…
A 122,000-person Cleveland Clinic study found that low cardiorespiratory fitness carries a greater mortality risk than smoking, diabetes, or coronary artery disease, with no upper limit of benefit. Inside the…
At ASCO 2026’s plenary session, ivonescimab, a first-in-class bispecific antibody targeting PD-1 and VEGF, cut the risk of death by 34% in advanced squamous NSCLC, becoming the first drug to…
Almost three decades after Makoto Kuro-o named the protein after the Greek Fate of life, UCSF’s Dena Dubal has launched the first human trial of klotho. Inside the cell biology,…
A landmark Nature study from Mass General Brigham analyzed 11,000+ gene expression profiles across four mammalian species and found that aging leaves the same molecular fingerprint in virtually every tissue…
A major study being presented this week at the American Society of Clinical Oncology’s annual meeting found that patients with early-stage cancer who took GLP-1 receptor agonists were 38 to…
The American Heart Association’s October 2025 scientific statement and a 60,000-person UK Biobank cohort have converged on a quiet but radical finding: when you sleep matters as much as how…
For the first time in U.S. medical history, every adult is being told to measure a single genetic blood marker that explains a hidden quarter of heart attack risk. Inside…
A new generation of human trials and mechanistic studies is converging on a striking conclusion: resistance training does not merely preserve muscle. It signals the brain. Inside the myokine biology,…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.